<DOC>
	<DOCNO>NCT00311805</DOCNO>
	<brief_summary>The goal study determine safety possible effectiveness various dos autologous ( one 's ) stem cell , deliver needle region leg poor blood flow patient block leg artery result claudication ( pain walking ) . Stem cell primitive cell produce bone marrow develop blood cell type cell . In addition determine whether new approach safe , diagnostic test may offer preliminary insight usefulness approach treat intermittent claudication - condition area leg lack enough oxygen blood flow keep leg muscle work well , cause pain cramp upon walk . This study double-blind , randomize study compare CD34-positive stem cell versus placebo agent ( salt water solution know normal saline ) . The patient 3:1 chance stem cell versus placebo . Regardless patient receive placebo treatment , patient undergo pre-treatment phase study , include stem cell mobilization apheresis procedure .</brief_summary>
	<brief_title>Autologous CD34+ Stem Cell Injection Severe Intermittent Claudication ( Leg Pain )</brief_title>
	<detailed_description />
	<mesh_term>Intermittent Claudication</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>Males female equal great 21 year old Patients infrainguinal atherosclerosis stenosis occlusion major vessel affect limb ( ) one follow artery : superficial femoral , popliteal , one infrapopliteal artery , is/are nonreconstructable . Patients symptom Severe Intermittent Claudication least 1 low limb persist least 6 month ( Rutherford Class 3 ) . Patients diagnosis Peripheral Arterial Disease ( PAD ) least 1 low limb secondary atherosclerosis , least 6 month . Patients successful aortic low extremity arterial surgery , angioplasty , lumbar sympathectomy within 3 month precede screen . Patients iliac disease amenable revascularization . Patients judge suitable candidate surgical percutaneous revascularization limb treatment propose . Patients Critical Limb Ischemia ( CLI ) , Rutherford Symptom Score 4,5 , 6 . Patients arterial insufficiency lower extremity result nonatherosclerotic disorder .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>